A grave neurodegenerative disease like Alzheimer’s whose cure is still unknown can now be managed with Dthera Sciences’ DTHR-ALZ, a novel digital therapy device which has been bestowed with the prestigious Breakthrough Device designation by the FDA.
Neurotrophic Keratitis (NK) is a rare eye disorder that affects the corneal sensation leading to a loss in vision. Till date, only invasive surgeries and palliative treatments were available to treat the disease. But now, there is a major breakthrough in this regard since the US-FDA has approved the Italian company Dompé’s eye drop, Oxervate in order to treat NK.
Four additional untried treatment solutions for the Ebola virus danger have received a green signal from the Democratic Republic of Congo as a move from the health ministry in its efforts to control the virus’ spread.
SPR Therapeutics’ single- and dual-lead peripheral nerve stimulation devices win FDA nod as minimally invasive, non-opioid alternatives to treat acute chronic, postoperative and post-traumatic pain when implanted for up to two months.
Bristol-Myers Squibb secured a standing in the small cell lung cancer domain making up for its slower growth in the non-small cell lung cancer market compared to its counterpart, Merck.
Obsessive-compulsive disorder (OCD) patients are now offered with a new treatment option as the FDA grants de novo approval for Brainsway’s deep transcranial magnetic stimulation (TMS) system.
Xolair of Novartis and Roche has been declared as a breakthrough therapy for food allergies including eggs, milk and peanuts by the Food and Drugs Administration (FDA).
The US-FDA (US- Food and Drugs Administration) announced on 13 August that it will permit the marketing of Natural Cycles’ contraception app in the US for pre-menopausal women aged 18 years and older.
Annovera (segesterone acetate and ethinyl estradiol vaginal system), a multi-use donut-shaped ring, was recently approved and presented to the Population Council by the FDA.
Healthcare professionals in northern New York need not wait anymore for the telemedicine program designed to screen patients for diabetic retinopathy.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.